Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P30044 (
antioxidant enzyme
)
8,037
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Fetal growth restriction (FGR) is a major cause of neonatal morbidity and mortality. There is evidence to show that FGR is associated with oxidative stress.
Lipoxin A4
(
LXA4
) is an anti-inflammatory mediator and is considered to be a potent endogenous "stop signal" in inflammation.
LXA4
has been extensively studied preclinically in many diseases related to inflammation. Recently, the antioxidant effect of
LXA4
on a variety of cell types has been reported. In the current study, we tested the effect of
LXA4
on rats with experimental FGR. Dexamethasone (DEX) was administered to pregnant rats in order to induce FGR and BML-111, a synthetic analog of
LXA4
, was administrated as antioxidant therapy. DEX caused increased oxidative stress and trophoblast cell apoptosis in the placenta, leading to decreased placental weight and fetal weight at term. These effects were partially alleviated by BML-111. As a possible mechanism for this improvement in weight, BML-111 was found to promote nuclear translocation of nuclear factor erythroid 2-related factor 2 (Nrf2), up-regulate the expression of
antioxidant enzyme
genes, superoxide dismutase (SOD) and glutathione peroxidase (GPx), and consequently inhibited trophoblast cells apoptosis. This study demonstrates for the first time that
LXA4
could potentially alleviate FGR in DEX-exposed pregnant rats.
...
PMID:A synthetic analog of lipoxin A4 partially alleviates dexamethasone-induced fetal growth restriction in rats. 2391 May 25
